<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577730</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00135919</org_study_id>
    <nct_id>NCT03577730</nct_id>
  </id_info>
  <brief_title>Caffeine and Neurologic Recovery Following Surgery and General Anesthesia</brief_title>
  <official_title>Caffeine and Neurologic Recovery Following Surgery and General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ongoing opioid epidemic is a public health crisis, and surgical patients are particularly
      vulnerable to opioid-dependency and related risks. Emerging data suggest that caffeine may
      reduce pain after surgery. Thus, the purpose of this study is to test whether caffeine
      reduces pain and opioid requirements after surgery. The investigators will also test whether
      caffeine improves mood and brain function (e.g., learning, memory) after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opioid-related deaths have quadrupled in the last 20 years, and nearly half of these deaths
      currently involve prescription opioids. Surgical patients often experience moderate-to-severe
      pain is common after major surgery, and surgery is associated with a 14-fold increased risk
      of opioid dependency compared to non-surgical controls, even after minor surgery.
      Furthermore, mood disorders (e.g., depression) are independently associated with persistent
      opioid use postoperatively, and signs of postoperative depression are common after major
      surgery. Thus, given these risk factors, surgical patients are at particularly high risk for
      opioid dependency postoperatively. Interventions that (1) reduce opioid burden, and (2)
      improve mood and neuropsychological function may mitigate the risk of postoperative opioid
      dependency. Preliminary laboratory and clinical findings demonstrate that caffeine may reduce
      pain after surgery, which may translate to lower opioid requirements. The study tests the
      hypothesis that intraoperative caffeine administration will improve opioid consumption, pain,
      and neuropsychological recovery in patients undergoing surgery. Through validated assessment
      measures, the research team will study the effects of caffeine in relation to postoperative
      opioid requirements, pain, and neuropsychological (e.g., cognition, depression, anxiety)
      trajectory after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Actual">January 17, 2020</completion_date>
  <primary_completion_date type="Actual">November 21, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This will be a single-center, quadruple-blinded, pilot randomized controlled trial at the University of Michigan Health System.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative opioid consumption: Postoperative opioid consumption, oral morphine equivalents (mg)</measure>
    <time_frame>through postoperative day 3</time_frame>
    <description>Postoperative opioid consumption, oral morphine equivalents (mg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute pain (patient-reported) as assessed by Visual Analogue Scale</measure>
    <time_frame>postoperative day 0-3</time_frame>
    <description>Visual Analogue Scale (mm, 0-100, 0 = no pain, 100 = worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute pain (observer-reported) as assessed by Behavioral Pain Scale</measure>
    <time_frame>postoperative day 0-3</time_frame>
    <description>Behavioral Pain Scale (n, 3-12, 3 = no pain, 12 = maximum pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until anesthetic emergence</measure>
    <time_frame>Duration of time from surgical dressing completion to anesthetic emergence (min); generally between 10 and 60 minutes</time_frame>
    <description>Time from surgical dressing on to anesthetic emergence (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms as assessed by Hospitalized Anxiety and Depression Scale (HADS-D)</measure>
    <time_frame>baseline through postoperative day 3</time_frame>
    <description>Incidence (%) of positive screens (score ≥8) using the Hospitalized Anxiety and Depression Scale (HADS-D) (n, 0-21, 0 = normal, 21 = presence of severe depression symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety symptoms as assessed by Hospitalized Anxiety and Depression Scale (HADS-A)</measure>
    <time_frame>baseline through postoperative day 3</time_frame>
    <description>Incidence (%) of positive screens (score ≥8) using the Hospitalized Anxiety and Depression Scale (HADS-A) (n, 0-21, 0 = normal, 21 = presence of severe anxiety symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function as assessed by Trail Making Test</measure>
    <time_frame>morning of surgery baseline compared to postanesthesia care unit. Postanesthesia care unit measurement approximately 60 minutes after end of surgery</time_frame>
    <description>Trail Making Test scores (seconds, 10-300,10 = fasted reported completion, 300 = maximum time allowed for completion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Affect as assessed by PANAS (Positive and Negative Affect Schedule)</measure>
    <time_frame>postoperative day 3 compared to baseline</time_frame>
    <description>Positive Affect Score (n, 10-50, 10 = least positive affect, 50 = most positive affect) via PANAS (Positive and Negative Affect Schedule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Affect as assessed by PANAS (Positive and Negative Affect Schedule)</measure>
    <time_frame>postoperative day 3 compared to baseline</time_frame>
    <description>Negative Affect Score (n, 10-50, 10 = least negative affect, 50 = most negative affect) via PANAS (Positive and Negative Affect Schedule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Delirious Patients per Group</measure>
    <time_frame>By afternoon of postoperative day (POD) 3</time_frame>
    <description>Each participant who has experienced at least one episode of delirium by the postoperative day 3 time point, as determined by daily Confusion Assessment Method (CAM) screening, will then be calculated in each group to provide delirium incidence (%).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Caffeine intake: Number of caffeinated beverages (n) consumed</measure>
    <time_frame>postoperative day 0-7</time_frame>
    <description>Number of caffeinated beverages (n) consumed</description>
  </other_outcome>
  <other_outcome>
    <measure>Subacute opioid consumption: Postoperative subacute opioid consumption, oral morphine equivalents (mg)</measure>
    <time_frame>postoperative days 4-7</time_frame>
    <description>Postoperative subacute opioid consumption, oral morphine equivalents (mg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep disturbances: Incidence (%) of new, self-reported sleep disturbances</measure>
    <time_frame>postoperative days 0-3</time_frame>
    <description>Incidence (%) of new, self-reported sleep disturbances</description>
  </other_outcome>
  <other_outcome>
    <measure>EEG spectral power: Spectral power (dB) measured on EEG</measure>
    <time_frame>time point 1: anesthetic emergence, approximate measurement 5-10 minutes after surgery end. Time point 2: postanesthesia care unit arrival, approximate measurement 20 minutes after end of surgery</time_frame>
    <description>Spectral power (dB) measured on EEG</description>
  </other_outcome>
  <other_outcome>
    <measure>EEG connectivity: Connectivity (weighted phase lag index, wPLI) measured on EEG</measure>
    <time_frame>time point 1: anesthetic emergence, approximate measurement 5-10 minutes after surgery end. Time point 2: postanesthesia care unit arrival, approximate measurement 20 minutes after end of surgery</time_frame>
    <description>Connectivity (weighted phase lag index, wPLI) measured on EEG</description>
  </other_outcome>
  <other_outcome>
    <measure>Veterans Rand 12 Survey</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Comprehensive survey that reports on general health perceptions, physical functioning, role limitations due to physical and emotional problems, bodily pain, energy /fatigue levels, social functioning and mental health. Specifically, a physical and mental health score are reported, with both score scales ranging from 0 (worst possible outcome) to 100 (best possible outcome).</description>
  </other_outcome>
  <other_outcome>
    <measure>Persistent opioid use</measure>
    <time_frame>Postoperative day (POD) 30</time_frame>
    <description>Incidence of continued opioid use (%) on postoperative day (POD) 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Recovery Survey</measure>
    <time_frame>Postoperative day (POD) 1</time_frame>
    <description>Self-report outcome measure evaluating recovery after surgery and anesthesia. Scoring ranges from 3-18, 3=poor 18=excellent</description>
  </other_outcome>
  <other_outcome>
    <measure>Richards Campbell Sleep Questionnaire (RCSQ)</measure>
    <time_frame>Preoperative (once before surgery on day of surgery)</time_frame>
    <description>Self-report instrument for measuring sleep quality. Visual Analogue Scale (mm, 0-100, 0 =Deep sleep , 100 =Light sleep)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine Citrate</intervention_name>
    <description>Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose Water</intervention_name>
    <description>Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt;/= 18 years old) undergoing non-cardiac, non-neurologic, non-major vascular
             surgery requiring general anesthesia

        Exclusion Criteria:

          -  Emergency surgery

          -  Cognitive impairment precluding capacity for informed consent

          -  Uncontrolled cardiac arrhythmias

          -  Seizure disorders

          -  Preoperative opioid use

          -  Diabetes

          -  Liver failure

          -  Pregnancy

          -  Breastfeeding

          -  Severe visual or auditory impairment (may hinder cognitive function testing)

          -  Patients unable to speak English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Vlisides, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Anesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michigan Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, Fu R, Azad T, Chao TE, Berry WR, Gawande AA. Estimate of the global volume of surgery in 2012: an assessment supporting improved health outcomes. Lancet. 2015 Apr 27;385 Suppl 2:S11. doi: 10.1016/S0140-6736(15)60806-6. Epub 2015 Apr 26.</citation>
    <PMID>26313057</PMID>
  </reference>
  <reference>
    <citation>Kundermann B, Krieg JC, Schreiber W, Lautenbacher S. The effect of sleep deprivation on pain. Pain Res Manag. 2004 Spring;9(1):25-32. Review.</citation>
    <PMID>15007400</PMID>
  </reference>
  <reference>
    <citation>Vaurio LE, Sands LP, Wang Y, Mullen EA, Leung JM. Postoperative delirium: the importance of pain and pain management. Anesth Analg. 2006 Apr;102(4):1267-73.</citation>
    <PMID>16551935</PMID>
  </reference>
  <reference>
    <citation>Lynch EP, Lazor MA, Gellis JE, Orav J, Goldman L, Marcantonio ER. The impact of postoperative pain on the development of postoperative delirium. Anesth Analg. 1998 Apr;86(4):781-5.</citation>
    <PMID>9539601</PMID>
  </reference>
  <reference>
    <citation>Karp JF, Reynolds CF 3rd, Butters MA, Dew MA, Mazumdar S, Begley AE, Lenze E, Weiner DK. The relationship between pain and mental flexibility in older adult pain clinic patients. Pain Med. 2006 Sep-Oct;7(5):444-52.</citation>
    <PMID>17014605</PMID>
  </reference>
  <reference>
    <citation>Dolan R, Huh J, Tiwari N, Sproat T, Camilleri-Brennan J. A prospective analysis of sleep deprivation and disturbance in surgical patients. Ann Med Surg (Lond). 2016 Jan 6;6:1-5. doi: 10.1016/j.amsu.2015.12.046. eCollection 2016 Mar.</citation>
    <PMID>26909151</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Curr Med Res Opin. 2014 Jan;30(1):149-60. doi: 10.1185/03007995.2013.860019. Epub 2013 Nov 15. Review.</citation>
    <PMID>24237004</PMID>
  </reference>
  <reference>
    <citation>Avidan MS, Maybrier HR, Abdallah AB, Jacobsohn E, Vlisides PE, Pryor KO, Veselis RA, Grocott HP, Emmert DA, Rogers EM, Downey RJ, Yulico H, Noh GJ, Lee YH, Waszynski CM, Arya VK, Pagel PS, Hudetz JA, Muench MR, Fritz BA, Waberski W, Inouye SK, Mashour GA; PODCAST Research Group. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Lancet. 2017 Jul 15;390(10091):267-275. doi: 10.1016/S0140-6736(17)31467-8. Epub 2017 May 30. Erratum in: Lancet. 2017 Jul 15;390(10091):230.</citation>
    <PMID>28576285</PMID>
  </reference>
  <reference>
    <citation>Pandharipande P, Cotton BA, Shintani A, Thompson J, Pun BT, Morris JA Jr, Dittus R, Ely EW. Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. J Trauma. 2008 Jul;65(1):34-41. doi: 10.1097/TA.0b013e31814b2c4d.</citation>
    <PMID>18580517</PMID>
  </reference>
  <reference>
    <citation>Robinson TN, Raeburn CD, Tran ZV, Angles EM, Brenner LA, Moss M. Postoperative delirium in the elderly: risk factors and outcomes. Ann Surg. 2009 Jan;249(1):173-8. doi: 10.1097/SLA.0b013e31818e4776.</citation>
    <PMID>19106695</PMID>
  </reference>
  <reference>
    <citation>Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, Bohnert ASB, Kheterpal S, Nallamothu BK. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017 Jun 21;152(6):e170504. doi: 10.1001/jamasurg.2017.0504. Epub 2017 Jun 21. Erratum in: JAMA Surg. 2019 Mar 1;154(3):272.</citation>
    <PMID>28403427</PMID>
  </reference>
  <reference>
    <citation>Saczynski JS, Marcantonio ER, Quach L, Fong TG, Gross A, Inouye SK, Jones RN. Cognitive trajectories after postoperative delirium. N Engl J Med. 2012 Jul 5;367(1):30-9. doi: 10.1056/NEJMoa1112923.</citation>
    <PMID>22762316</PMID>
  </reference>
  <reference>
    <citation>Bickel H, Gradinger R, Kochs E, Förstl H. High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study. Dement Geriatr Cogn Disord. 2008;26(1):26-31. doi: 10.1159/000140804. Epub 2008 Jun 24.</citation>
    <PMID>18577850</PMID>
  </reference>
  <reference>
    <citation>Nelson AM, Battersby AS, Baghdoyan HA, Lydic R. Opioid-induced decreases in rat brain adenosine levels are reversed by inhibiting adenosine deaminase. Anesthesiology. 2009 Dec;111(6):1327-33. doi: 10.1097/ALN.0b013e3181bdf894.</citation>
    <PMID>19934879</PMID>
  </reference>
  <reference>
    <citation>Gauthier EA, Guzick SE, Brummett CM, Baghdoyan HA, Lydic R. Buprenorphine disrupts sleep and decreases adenosine concentrations in sleep-regulating brain regions of Sprague Dawley rat. Anesthesiology. 2011 Oct;115(4):743-53. doi: 10.1097/ALN.0b013e31822e9f85.</citation>
    <PMID>21857500</PMID>
  </reference>
  <reference>
    <citation>Osman NI, Baghdoyan HA, Lydic R. Morphine inhibits acetylcholine release in rat prefrontal cortex when delivered systemically or by microdialysis to basal forebrain. Anesthesiology. 2005 Oct;103(4):779-87.</citation>
    <PMID>16192770</PMID>
  </reference>
  <reference>
    <citation>Pisani MA, Murphy TE, Araujo KL, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med. 2009 Jan;37(1):177-83. doi: 10.1097/CCM.0b013e318192fcf9.</citation>
    <PMID>19050611</PMID>
  </reference>
  <reference>
    <citation>Litaker D, Locala J, Franco K, Bronson DL, Tannous Z. Preoperative risk factors for postoperative delirium. Gen Hosp Psychiatry. 2001 Mar-Apr;23(2):84-9.</citation>
    <PMID>11313076</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Phillip Vlisides</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Opioid Use</keyword>
  <keyword>Opioid Dependence</keyword>
  <keyword>Opioid-Related Disorders</keyword>
  <keyword>Opioid Abuse</keyword>
  <keyword>Opioid-use Disorder</keyword>
  <keyword>Pain</keyword>
  <keyword>Pain, Postoperative</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Delirium</keyword>
  <keyword>Delirium on Emergence</keyword>
  <keyword>Depression</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Anxiety Disorders</keyword>
  <keyword>Affect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Caffeine citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

